Addendum

Nusinersen (spinal muscular atrophy) - Addendum to Commission A20-114

Report documents

Indication:

Patients with 5q spinal muscular atrophy (SMA)

Result of dossier assessment:

Patients with early onset of disease (infantile form, SMA type 1): indication of major added benefit.

Patients with later onset of disease (SMA type 2, type 3 and type 4): added benefit not proven.

Pre-symptomatic patients with 5q SMA: hint of non-quantifiable added benefit.

Federal Joint Committee (G-BA)

2021.05.20 A G-BA decision was published.

Project no.: A21-43
Commission: Commission awarded on 07.04.2021 by the Federal Joint Committee (GBA).
Report type: Addendum
Status: Commission completed
Department/Division: Drug Assessment
Topic: Muscles, bones and joints
Note: If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.